
Nikolaos Grigoriadis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4444123/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1386-1395.	1.9	280
2	Can We Design a Nogo Receptor-Dependent Cellular Therapy to Target MS?. Cells, 2019, 8, 1.	4.1	170
3	Transplanted neural precursor cells reduce brain inflammation to attenuate chronic experimental autoimmune encephalomyelitis. Experimental Neurology, 2006, 198, 275-284.	4.1	154
4	Eradication of Helicobacter pylori may be beneficial in the management of Alzheimer's disease. Journal of Neurology, 2009, 256, 758-767.	3.6	150
5	Neurological manifestations of long-COVID syndrome: a narrative review. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232210768.	2.5	120
6	Neurological manifestations and implications of COVID-19 pandemic. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642093203.	3.5	114
7	Transplanted Neural Precursors Enhance Host Brain-Derived Myelin Regeneration. Journal of Neuroscience, 2009, 29, 15694-15702.	3.6	112
8	Five-year Survival After Helicobacter pylori Eradication in Alzheimer Disease Patients. Cognitive and Behavioral Neurology, 2010, 23, 199-204.	0.9	94
9	Variable behavior and complications of autologous bone marrow mesenchymal stem cells transplanted in experimental autoimmune encephalomyelitis. Experimental Neurology, 2011, 230, 78-89.	4.1	86
10	Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options. Autoimmunity Highlights, 2019, 10, 7.	3.9	84
11	Epidemiology of Patent Foramen Ovale in General Population and in Stroke Patients: A Narrative Review. Frontiers in Neurology, 2020, 11, 281.	2.4	76
12	Helicobacter pylori infection and gastric cancer biology: tempering a double-edged sword. Cellular and Molecular Life Sciences, 2019, 76, 2477-2486.	5.4	59
13	Microbiome in Multiple Sclerosis: Where Are We, What We Know and Do Not Know. Brain Sciences, 2020, 10, 234.	2.3	59
14	Tauopathy in the young autistic brain: novel biomarker and therapeutic target. Translational Psychiatry, 2020, 10, 228.	4.8	57
15	The Role of Diet and Interventions on Multiple Sclerosis: A Review. Nutrients, 2022, 14, 1150.	4.1	52
16	Helicobacter pylori and multiple sclerosis. Journal of Neuroimmunology, 2007, 188, 187-189.	2.3	50
17	Neuroinflammation in multiple sclerosis: Evidence for autoimmune dysregulation, not simple autoimmune reaction. Clinical Neurology and Neurosurgery, 2006, 108, 241-244.	1.4	49
18	Titanium dioxide photocatalytic inactivation of prions. Journal of General Virology, 2006, 87, 3125-3130.	2.9	47

NIKOLAOS GRIGORIADIS

#	Article	IF	CITATIONS
19	Axonal damage in multiple sclerosis: a complex issue in a complex disease. Clinical Neurology and Neurosurgery, 2004, 106, 211-217.	1.4	44
20	The autism/neuroprotection-linked ADNP/NAP regulate the excitatory glutamatergic synapse. Translational Psychiatry, 2019, 9, 2.	4.8	42
21	Time Course and Spatial Profile of Nogo-A Expression in Experimental Autoimmune Encephalomyelitis in C57BL/6 Mice. Journal of Neuropathology and Experimental Neurology, 2012, 71, 907-920.	1.7	40
22	COVID-19 Immunopathology and the Central Nervous System: Implication for Multiple Sclerosis and Other Autoimmune Diseases with Associated Demyelination. Brain Sciences, 2020, 10, 345.	2.3	38
23	The Effect of Disease Modifying Therapies on Brain Atrophy in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0116511.	2.5	37
24	Efficacy of a Computer-Assisted Cognitive Rehabilitation Intervention in Relapsing-Remitting Multiple Sclerosis Patients: A Multicenter Randomized Controlled Trial. Behavioural Neurology, 2017, 2017, 1-17.	2.1	37
25	Cardio-cerebrovascular disease and Helicobacter pylori-related metabolic syndrome: We consider eradication therapy as a potential cardio-cerebrovascular prevention strategy. International Journal of Cardiology, 2017, 229, 17-18.	1.7	36
26	EEG Window Length Evaluation for the Detection of Alzheimer's Disease over Different Brain Regions. Brain Sciences, 2019, 9, 81.	2.3	35
27	Analysis of electroencephalographic signals complexity regarding Alzheimer's Disease. Computers and Electrical Engineering, 2019, 76, 198-212.	4.8	35
28	Virus-mediated autoimmunity in Multiple Sclerosis. Journal of Autoimmune Diseases, 2006, 3, 1.	1.0	33
29	Viruses and Multiple Sclerosis: From Mechanisms and Pathways to Translational Research Opportunities. Molecular Neurobiology, 2017, 54, 3911-3923.	4.0	33
30	Novel ADNP Syndrome Mice Reveal Dramatic Sex-Specific Peripheral Gene Expression With Brain Synaptic and Tau Pathologies. Biological Psychiatry, 2022, 92, 81-95.	1.3	32
31	From the "little brain―gastrointestinal infection to the "big brain―neuroinflammation: A proposed fast axonal transport pathway involved in multiple sclerosis. Medical Hypotheses, 2009, 73, 781-787.	1.5	31
32	The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0144538.	2.5	31
33	Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks. Multiple Sclerosis International, 2016, 2016, 1-8.	0.8	30
34	Exercise training attenuates experimental autoimmune encephalomyelitis by peripheral immunomodulation rather than direct neuroprotection. Experimental Neurology, 2018, 299, 56-64.	4.1	26
35	The effect of disease-modifying therapies on brain atrophy in patients with clinically isolated syndrome: a systematic review and meta-analysis. Therapeutic Advances in Neurological Disorders, 2015, 8, 193-202.	3.5	24
36	Nogo receptor complex expression dynamics in the inflammatory foci of central nervous system experimental autoimmune demyelination. Journal of Neuroinflammation, 2016, 13, 265.	7.2	24

NIKOLAOS GRIGORIADIS

#	Article	IF	CITATIONS
37	Replication study of GWAS risk loci in Greek multiple sclerosis patients. Neurological Sciences, 2019, 40, 253-260.	1.9	24
38	Time-dependent fate of transplanted neural precursor cells in experimental autoimmune encephalomyelitis mice. Experimental Neurology, 2011, 230, 16-26.	4.1	23
39	The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials. PLoS ONE, 2016, 11, e0163296.	2.5	23
40	Do Secondary Progressive Multiple Sclerosis patients benefit from Computer- based cognitive neurorehabilitation? A randomized sham controlled trial. Multiple Sclerosis and Related Disorders, 2020, 39, 101932.	2.0	23
41	High-Intensity Exercise Training Protects the Brain Against Autoimmune Neuroinflammation: Regulation of Microglial Redox and Pro-inflammatory Functions. Frontiers in Cellular Neuroscience, 2021, 15, 640724.	3.7	22
42	A potential impact of Helicobacter pylori -related galectin-3 in neurodegeneration. Neurochemistry International, 2018, 113, 137-151.	3.8	21
43	Concentric demyelination pattern in COVID-19-associated acute haemorrhagic leukoencephalitis: a lurking catastrophe?. Brain, 2020, 143, e100-e100.	7.6	21
44	The role of cognitive reserve in multiple sclerosis: A cross-sectional study in 526 patients. Multiple Sclerosis and Related Disorders, 2020, 41, 102047.	2.0	20
45	Rodent models of obesity. Minerva Endocrinologica, 2020, 45, 243-263.	1.8	20
46	"Liberation treatment―for chronic cerebrospinal venous insufficiency in multiple sclerosis: the truth will set you free. Brain and Behavior, 2015, 5, 3-12.	2.2	19
47	Longâ€ŧerm effects of autoimmune CNS inflammation on adult hippocampal neurogenesis. Journal of Neuroscience Research, 2017, 95, 1446-1458.	2.9	19
48	Atypical Auditory Brainstem Response and Protein Expression Aberrations Related to ASD and Hearing Loss in the Adnp Haploinsufficient Mouse Brain. Neurochemical Research, 2019, 44, 1494-1507.	3.3	19
49	A concept of Helicobacter pylori and stress-secreted mast cells' potential involvement in brain metastases. Journal of Neuroimmunology, 2009, 209, 121-122.	2.3	18
50	Dysphagia Prevalence, Attitudes, and Related Quality of Life in Patients with Multiple Sclerosis. Dysphagia, 2020, 35, 677-684.	1.8	18
51	Tongue strength, dysphagia questionnaire, pharyngeal secretions and FEES findings in dysphagia management in amyotrophic lateral sclerosis. Auris Nasus Larynx, 2021, 48, 672-682.	1.2	18
52	Interferon β treatment in relapsing–remitting multiple sclerosis. A review. Clinical Neurology and Neurosurgery, 2002, 104, 251-258.	1.4	17
53	Helicobacter pylori with or without its neutrophil-activating protein may be the common denominator associated with multiple sclerosis and neuromyelitis optica. Multiple Sclerosis Journal, 2010, 16, 376-377.	3.0	17
54	Connexin43 and connexin47 alterations after neural precursor cells transplantation in experimental autoimmune encephalomyelitis. Glia, 2015, 63, 1772-1783.	4.9	17

NIKOLAOS GRIGORIADIS

#	Article	IF	CITATIONS
55	The Rationale for Monitoring Cognitive Function in Multiple Sclerosis: Practical Issues for Clinicians. The Open Neurology Journal, 2018, 12, 31-40.	0.4	17
56	Exercise intensityâ€dependent immunomodulatory effects on encephalomyelitis. Annals of Clinical and Translational Neurology, 2019, 6, 1647-1658.	3.7	17
57	Cognitive and brain reserve in multiple sclerosis––A cross-sectional study. Multiple Sclerosis and Related Disorders, 2019, 35, 128-134.	2.0	17
58	Oxidative Stress and Neurodegeneration: Interconnected Processes in PolyQ Diseases. Antioxidants, 2021, 10, 1450.	5.1	17
59	Spatio-temporal expression profile of NGF and the two-receptor system, TrkA and p75NTR, in experimental autoimmune encephalomyelitis. Journal of Neuroinflammation, 2020, 17, 41.	7.2	17
60	Gene variants of adhesion molecules act as modifiers of disease severity in MS. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e350.	6.0	15
61	Serotoninergic system targeting in multiple sclerosis: the prospective for pathogenetic therapy Multiple Sclerosis and Related Disorders, 2021, 51, 102888.	2.0	15
62	An Update on the Role of Matrix Metalloproteinases in the Pathogenesis of Multiple Sclerosis. Medicinal Chemistry, 2018, 14, 155-169.	1.5	15
63	Gene variants of adhesion molecules predispose to MS: A case-control study. Neurology: Genetics, 2019, 5, e304.	1.9	14
64	The Administrative Prevalence of Multiple Sclerosis in Greece on the Basis of a Nationwide Prescription Database. Frontiers in Neurology, 2020, 11, 1012.	2.4	14
65	Reliability and validity of the DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis (Greek version) and proposed modification. Multiple Sclerosis and Related Disorders, 2018, 23, 62-68.	2.0	13
66	Helicobacter pylori infection as a risk factor for primary open-angle glaucoma. Clinical and Experimental Ophthalmology, 2008, 36, 196-196.	2.6	12
67	Potential impact of Helicobacter pylori-related Galectin-3 on chronic kidney, cardiovascular and brain disorders in decompensated cirrhosis. Digestive and Liver Disease, 2020, 52, 121-123.	0.9	12
68	Exposure to 3-Nitropropionic Acid Mitochondrial Toxin Induces Tau Pathology in Tangle-Mouse Model and in Wild Type-Mice. Frontiers in Cell and Developmental Biology, 2019, 7, 321.	3.7	12
69	Persistent decline of hospitalizations for acute stroke and acute coronary syndrome during the second wave of the COVID-19 pandemic in Greece: collateral damage unaffected. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110295.	3.5	12
70	Subcutaneous Transplantation of Neural Precursor Cells in Experimental Autoimmune Encephalomyelitis Reduces Chemotactic Signals in the Central Nervous System. Stem Cells Translational Medicine, 2015, 4, 1450-1462.	3.3	11
71	Cyclic MOG 35 – 55 ameliorates clinical and neuropathological features of experimental autoimmune encephalomyelitis. Bioorganic and Medicinal Chemistry, 2017, 25, 4163-4174.	3.0	11
72	Continuous and interval training attenuate encephalomyelitis by separate immunomodulatory mechanisms. Annals of Clinical and Translational Neurology, 2021, 8, 190-200.	3.7	11

#	Article	IF	CITATIONS
73	B-cells expressing NgR1 and NgR3 are localized to EAE-induced inflammatory infiltrates and are stimulated by BAFF. Scientific Reports, 2021, 11, 2890.	3.3	11
74	Health 4.0: The case of multiple sclerosis. , 2016, , .		9
75	Multiple Sclerosis: Shall We Target CD33?. Genes, 2020, 11, 1334.	2.4	9
76	Symbol Digit Modalities Test: Greek Normative Data for the Oral and Written Version and Discriminative Validity in Patients with Multiple Sclerosis. Archives of Clinical Neuropsychology, 2021, 36, 117-125.	0.5	9
77	The trimebutine effect on Helicobacter pylori-related gastrointestinal tract and brain disorders: A hypothesis. Neurochemistry International, 2021, 144, 104938.	3.8	9
78	Signaling through the S1Pâ^'S1PR Axis in the Gut, the Immune and the Central Nervous System in Multiple Sclerosis: Implication for Pathogenesis and Treatment. Cells, 2021, 10, 3217.	4.1	9
79	p75NTR and TROY: Uncharted Roles of Nogo Receptor Complex in Experimental Autoimmune Encephalomyelitis. Molecular Neurobiology, 2018, 55, 6329-6336.	4.0	8
80	TREM2 R47H (rs75932628) variant is unlikely to contribute to Multiple Sclerosis susceptibility and severity in a large Greek MS cohort. Multiple Sclerosis and Related Disorders, 2019, 35, 116-118.	2.0	8
81	Brief international cognitive assessment for multiple sclerosis (BICAMS) cut-off scores for detecting cognitive impairment in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 49, 102751.	2.0	8
82	Computerized cognitive rehabilitation for treatment of cognitive impairment in multiple sclerosis: an explorative study. Journal of Integrative Neuroscience, 2020, 19, 341.	1.7	8
83	Characterization of In Vitro Expanded Bone Marrow-Derived Mesenchymal Stem Cells Isolated from Experimental Autoimmune Encephalomyelitis Mice. Journal of Molecular Neuroscience, 2013, 51, 282-297.	2.3	7
84	Muscular dystrophy in a patient with multiple sclerosis. Another "double-trouble�. Multiple Sclerosis and Related Disorders, 2015, 4, 342-344.	2.0	7
85	Humoral response in experimental autoimmune encephalomyelitis targets neural precursor cells in the central nervous system of naive rodents. Journal of Neuroinflammation, 2017, 14, 227.	7.2	7
86	Cyclization of PLP139-151 peptide reduces its encephalitogenic potential in experimental autoimmune encephalomyelitis. Bioorganic and Medicinal Chemistry, 2018, 26, 2221-2228.	3.0	7
87	Prevalence of patent foramen ovale in the Greek population is high and impacts on the interpretation of the risk of paradoxical embolism (RoPE) score. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642096467.	3.5	7
88	Clinically reliable cognitive decline in relapsing remitting multiple sclerosis: Is it the tip of the iceberg?. Neurological Research, 2020, 42, 575-586.	1.3	7
89	Cognitive Fatigability is Independent of Subjective Cognitive Fatigue and Mood in Multiple Sclerosis. Cognitive and Behavioral Neurology, 2020, 33, 113-121.	0.9	7
90	Lumbar spine intrathecal transplantation of neural precursor cells promotes oligodendrocyte proliferation in hot spots of chronic demyelination. Brain Pathology, 2022, 32, e13040.	4.1	7

#	Article	IF	CITATIONS
91	Recovery, innervation profile, and contractile properties of reinnervating fast muscles following postnatal nerve crush and administration of l-Dopa. Developmental Brain Research, 2004, 153, 79-87.	1.7	6
92	Animal Models of Central Nervous System Immune-Mediated Diseases: Therapeutic Interventions with Bioactive Peptides and Mimetics. Current Medicinal Chemistry, 2005, 12, 1513-1519.	2.4	6
93	Biomarkers in Rare Demyelinating Disease of the Central Nervous System. International Journal of Molecular Sciences, 2020, 21, 8409.	4.1	6
94	Potential impact of Helicobacter pylori-related metabolic syndrome and Galectin-3 on liver, chronic kidney and brain disorders. Metabolism: Clinical and Experimental, 2021, 118, 154736.	3.4	6
95	Induction of apoptosis in CD4(+) T-cells is linked with optimal treatment response in patients with relapsing-remitting multiple sclerosis treated with Glatiramer acetate. Journal of the Neurological Sciences, 2019, 401, 43-50.	0.6	5
96	Reduced expression of L-selectin in T-cells correlates with relative lymphocyte increase in patients with RRMS treated with natalizumab - functional implication towards PML risk. Neurological Research, 2020, 42, 209-221.	1.3	5
97	Progressive multifocal leukoencephalopathy in an elderly immunocompetent-appearing patient: Relevance with L-selectin (CD62L) expression and immunosenescence. Clinical Neurology and Neurosurgery, 2021, 205, 106625.	1.4	5
98	Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center. Frontiers in Neurology, 2021, 12, 699844.	2.4	5
99	Helicobacter pylori eradication to prevent cardio-cerebrovascular disease: Are current data useful for clinical practice?. International Journal of Cardiology, 2017, 233, 92.	1.7	4
100	White matter hyperintensities in myotonic dystrophy type 2: Not always another expression of the disease. Multiple Sclerosis and Related Disorders, 2018, 24, 117-119.	2.0	4
101	Neuropsychological correlates of cerebellar volumes in multiple sclerosis: an MRI volumetric analysis study. Journal of Integrative Neuroscience, 2022, 21, 013.	1.7	4
102	Considerations on long-term immuno-intervention in the treatment of multiple sclerosis: an expert opinion. Expert Opinion on Pharmacotherapy, 2016, 17, 2085-2095.	1.8	3
103	Immunophenotype of mouse cerebral hemispheres-derived neural precursor cells. Neuroscience Letters, 2016, 611, 33-39.	2.1	3
104	Hereditary diffuse leukoencephalopathy with spheroids mimicking primary progressive aphasia: report of a Greek case. Neurological Sciences, 2021, 42, 3431-3433.	1.9	3
105	A Greek Validation Study of the Multiple Sclerosis Work Difficulties Questionnaire-23. Healthcare (Switzerland), 2021, 9, 897.	2.0	3
106	Helicobacter Pylori-Related Vitamin B12 Deficiency: A Potential Contributor in Neuropsychiatric Disorders. Indian Journal of Psychological Medicine, 2015, 37, 475-476.	1.5	3
107	A National Representative, Cross-Sectional Study by the Hellenic Academy of NeuroImmunology (HEL.A.NI.) on COVID-19 and Multiple Sclerosis: Overall Impact and Willingness Toward Vaccination. Frontiers in Neurology, 2021, 12, 757038.	2.4	3
108	The Multiple Sclerosis Data Alliance Catalogue. International Journal of MS Care, 2021, 23, 261-268.	1.0	3

#	Article	IF	CITATIONS
109	Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response. Cells, 2022, 11, 1959.	4.1	3
110	A â€~Posterior Circulation Stroke' that Benefits from Vitamins. American Journal of Medicine, 2014, 127, e1-e2.	1.5	2
111	Telmisartan-mediated metabolic profile conferred brain protection in diabetic hypertensive rats as evidenced by magnetic resonance imaging, behavioral studies and histology. European Journal of Pharmacology, 2016, 789, 88-97.	3.5	2
112	Commentary on: Comparing the efficacy of disease-modifying therapies in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 21, 117-119.	2.0	2
113	Application of antibody phage display to identify potential antigenic neural precursor cell proteins. Journal of Biological Research, 2020, 27, 14.	2.1	2
114	Primary progression in NMOSD. Does it really exist?. Multiple Sclerosis and Related Disorders, 2021, 48, 102712.	2.0	2
115	What scans see when patients see defects: neuroimaging findings in body dysmorphic disorder. Journal of Integrative Neuroscience, 2022, 21, 045.	1.7	2
116	Comparison of the Greek Version of the Quick Mild Cognitive Impairment Screen and Montreal Cognitive Assessment in Older Adults. Healthcare (Switzerland), 2022, 10, 906.	2.0	2
117	Estimating Everyday Neuropsychological Functioning in Multiple Sclerosis: Reliability and Validity of the Greek Multiple Sclerosis Neuropsychological Questionnaire. Multiple Sclerosis International, 2018, 2018, 1-6.	0.8	1
118	Comment on: "Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis― CNS Drugs, 2019, 33, 293-295.	5.9	1
119	Acute Pain in the Neck: Don't Miss the Crown!. Neurohospitalist, The, 2020, 10, 318-319.	0.8	1
120	Novel frameshift variant of NHLRC1 gene in compound heterozygosity in an adult Greek patient with Lafora disease. Seizure: the Journal of the British Epilepsy Association, 2021, 86, 49-51.	2.0	1
121	Spastic gait, intellectual disability and seizures due to a rare mutation causing hyperargininemia. Clinical Neurology and Neurosurgery, 2021, 208, 106895.	1.4	1
122	Novel contributors to B cell activation during inflammatory CNS demyelination; An oNGOing process. International Journal of Medical Sciences, 2022, 19, 164-174.	2.5	1
123	Teaching Neurolmage: Carotid Web: A Thrombogenic Nest Not to Miss. Neurology, 2022, , 10.1212/WNL.000000000013321.	1.1	1
124	"Radiologically Isolated―Spinal Cavernoma Associated with Familial Cerebral Cavernomatosis. European Neurology, 2019, 81, 327-330.	1.4	0
125	Encephalomyelitis and Lymphadenopathy in a Man in His Early 40s. JAMA Neurology, 2020, 77, 1171.	9.0	0
126	Off-label intravenous thrombolysis for early recurrent brain embolism associated with aortic arch thrombus. Neurological Research and Practice, 2021, 3, 4.	2.0	0

#	Article	IF	CITATIONS
127	Psychopharmacology of patients with multiple sclerosis in Greece during the period 2017-2019. Psychiatrikē = Psychiatriki, 2022, , .	0.6	Ο
128	An unusual phenotype of Acute Motor Sensory Axonal Neuropathy with ophthalmoplegia and <scp>antiâ€GD1a</scp> , ― <scp>GD1b</scp> , ― <scp>GM1</scp> antibodies. Clinical and Experimental Neuroimmunology, 0, , .	1.0	0